Eagle Point Credit Company Common Share of Beneficial Interest (ECC)
Live price chart, market sentiment, and community perspectives for Eagle Point Credit Company Common Share of Beneficial Interest (NYSE: ECC).
Live price chart, market sentiment, and community perspectives for Eagle Point Credit Company Common Share of Beneficial Interest (NYSE: ECC).
On our desk, sentiment toward ECC common stock remains deeply cautious given the year-to-date drop of over 33%. Even though Q2 2026 showed a brief NAV rebound to $4.51 (softening to $4.38 by July 31), the underlying structural gap between the dividend payout and net investment income of $0.17 per share keeps raising red flags about future distribution cuts and ongoing NAV decay.
Looking at the balance sheet risk, leverage ended Q2 at 47%, which is uncomfortably high compared to management's 35% target. Combined with $0.79 per share of realized investment losses and a weak GF Score of 25/100, the risk profile on the common shares demands strict downside hedging or an outright pivot toward their perpetual preferred options like ECC-D.
When analyzing ECC's portfolio rotation during the earnings call, management emphasized their pivot away from pure CLOs into regulatory capital relief securities and private credit. The most prominent example is the $1.3 billion mezzanine loan for the Nexus Data Centers campus in Texas anchored by Anthropic, illustrating how the operating firm continues to deploy capital into low-20s yield opportunities despite loan spread compression.
From our quantitative risk metrics, ECC's current Price-to-Sales ratio sits significantly below its historical median of 6.7x. While the 12.7% GAAP return on common equity in Q2 looked impressive on the surface due to temporary loan price recoveries, the fundamental cash flow constraints and elevated leverage suggest that chasing the common stock yield carries a high probability of capital loss.
From a credit and fixed-income perspective, the perpetual preferred share (ECC.PR.D) looks vastly superior to the common equity right now. Offering over a 9% yield with nearly 4x NII coverage, monthly payouts, and strong regulatory asset coverage, it provides capital preservation advantages that insulate income-focused accounts from common-share volatility.
Explore plasma cleansing, somatic organ swaps, and BCI.